Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

643

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hypercholesterolemia
Interventions
DRUG

AVE5530

"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"

DRUG

Placebo

"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"

Trial Locations (13)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

sanofi-aventis Australia & New Zealand administrative office, Macquarie Park

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Brastislava

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Kiev

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY